MG
IONS icon

Mather Group’s Ionis Pharmaceuticals IONS Stock Holding History

Mather Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.5K Hold
410
– – ﹤0.01% 1214
2026
Q1 		$30.8K Buy
+410
New +$32.4K ﹤0.01% 1168
2025
Q4 		– Sell
-410
Closed -$26.8K – 1131
2025
Q3 		$26.8K Buy
+410
New +$20K ﹤0.01% 1055
2025
Q2 		– Sell
-410
Closed -$12.4K – 1152
2025
Q1 		$12.4K Sell
410
-241
-37% -$7.89K ﹤0.01% 1198
2024
Q4 		$22.8K Buy
651
+135
+26% +$5.05K ﹤0.01% 1054
2024
Q3 		$20.7K Sell
516
-395
-43% -$18.4K ﹤0.01% 1056
2024
Q2 		$39.5K Buy
911
+240
+36% +$9.84K ﹤0.01% 1062
2024
Q1 		$33.9K Buy
+671
New +$32K ﹤0.01% 951

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Mather Group's IONS Position: Q2 2026 in Review

Mather Group held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 410 shares worth $32.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

Mather Group first reported a position in IONS in Q1 2024 and has held it in 8 quarters since. The position peaked at $39.5K in Q2 2024. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Mather Group held 410 shares of Ionis Pharmaceuticals worth $32.5K as of Q2 2026.
  • Mather Group left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1214 holding.
  • Mather Group first reported a position in Ionis Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • Mather Group's Ionis Pharmaceuticals position peaked at $39.5K in Q2 2024.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.